Versiti becomes 10th U.S. blood center to adopt FDA-cleared automation from Terumo Blood and Cell Technologies
Automated whole blood processing will expand platelet production capacity and help meet growing hospital demand LAKEWOOD, Colo. and MILWAUKEE, Oct. 19, 2026 /PRNewswire/ -- Versiti has become the 10th U.S. blood center to adopt the Reveos™ Automated Blood Processing System from Terumo Blood and Cell Technologies (Terumo BCT). Combined with the...
Alloop Joins CaringKind’s 38th Annual Alzheimer’s Walk and Brain Health Day
NEW YORK, Oct. 19, 2026 /PRNewswire/ -- Alloop participated in CaringKind's 38th Annual Alzheimer's Walk and Brain Health Day in Central Park on October 17. The team joined the walk and hosted an on-site booth alongside people living with Alzheimer's disease and related dementias, families, caregivers, and community advocates. Alloop Joins CaringKind’s 38th Annual Alzheimer’s Walk and...
Bambusa Therapeutics Presents Detailed BBT001 Atopic Dermatitis Proof-of-Concept Results at ISAD 2026
Detailed findings from a randomized, double-blind, placebo-controlled cohort presented by Eric Simpson, M.D., M.C.R., of Oregon Health & Science University Presentation brings previously announced clinical findings together with pharmacokinetic and biomarker evidence for scientific discussion Bambusa continues subcutaneous evaluation of BBT001 and preparations for Phase 2b development BOSTON, Oct. 19, 2026...
POMDOCTOR LIMITED Announces the Termination of Its ADR Program and Trade Class A Ordinary Shares on Nasdaq
GUANGZHOU, China, Oct. 19, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing artificial intelligence ("AI")-enabled healthcare solutions, today announced that it has commenced to terminate its American Depositary Receipt program (the "ADR Program"), including the termination of the related deposit agreement, as amended, and list the Company's Class...
Transcenta Therapeutics Announces Appointment of Ms. Jennie Ma as Chief Financial Officer
SUZHOU, China and PRINCETON, N.J., Oct. 19, 2026 /PRNewswire/ -- Transcenta Therapeutics (HKEX: 06628) today announced that its Board of Directors has approved the appointment of Ms. Jennie Ma as Chief Financial Officer (CFO) of the Company. In this role, Ms. Ma will oversee the Company's financial management, capital markets activities, investor relations, and strengthening its corporate compliance...
Akeso Announces Opening of Global Phase II Study of Ivonescimab in First-Line Clear Cell Renal Cell Carcinoma, Including Combination with Cadonilimab
HONG KONG, Oct. 19, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") and its partner Summit Therapeutics Inc. jointly announced an international multicenter Phase II clinical study (SMT112-216 / AK112-216 / NCT07877194). Built on Akeso's first-in-class immuno-oncology (IO) cornerstone therapy ivonescimab (PD-1/VEGF bispecific antibody), the study will assess the efficacy and safety of multiple treatment regimens, including...
OncoC4 Announces NMPA Acceptance of Two IND Applications for Cesalatamig Combination Studies with ADCs and Pan-RAS Inhibitors
— New Studies Expand Cesalatamig into Biomarker-driven Precision Immuno-oncology Strategies — Cesalatamig is Also Being Evaluated in Ongoing Phase 2 Studies in the United States and in China ROCKVILLE, Md. , Oct. 19, 2026 /PRNewswire/ -- OncoC4 Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer and neurodegenerative diseases, today...
Julia Gillard joins Hakluyt’s International Advisory Board
LONDON, Oct. 19, 2026 /PRNewswire/ -- Hakluyt, the global strategic advisory firm for businesses and investors, is delighted to announce the appointment of The Honourable Julia Gillard AC, former prime minister of Australia and current chair of Wellcome, to its international advisory board. Julia Gillard Julia Gillard is one of Australia's most prominent political leaders...
Health Innovation South West and Helfie AI announce partnership to evaluate digital-first hypertension screening
Findings from real-world settings will add to the evidence base for preventing cardiovascular disease MELBOURNE, Australia, Oct. 19, 2026 /PRNewswire/ -- Helfie AI and UK-based Health Innovation South West have announced a partnership to explore how digital-first approaches to hypertension screening can support earlier identification of people at risk of high...
Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.
Collaboration establishes a framework for a dedicated U.S. source of astatine-211 (211At), a scarce, next-generation alpha-emitting isotope with significant potential in targeted alpha therapy (TAT). Secures long-term, priority isotope access for Telix's alpha therapy pipeline, including its TLX102-Tx candidate for glioblastoma and leptomeningeal disease, while also supporting third-party academic and...
